These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 30229274

  • 1. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA, UNITED study.
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [Abstract] [Full Text] [Related]

  • 2. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT.
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [Abstract] [Full Text] [Related]

  • 3. Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.
    Carlsson A, Shepherd M, Ellard S, Weedon M, Lernmark Å, Forsander G, Colclough K, Brahimi Q, Valtonen-Andre C, Ivarsson SA, Elding Larsson H, Samuelsson U, Örtqvist E, Groop L, Ludvigsson J, Marcus C, Hattersley AT.
    Diabetes Care; 2020 Jan; 43(1):82-89. PubMed ID: 31704690
    [Abstract] [Full Text] [Related]

  • 4. MODY in Ukraine: genes, clinical phenotypes and treatment.
    Globa E, Zelinska N, Elblova L, Dusatkova P, Cinek O, Lebl J, Colclough K, Ellard S, Pruhova S.
    J Pediatr Endocrinol Metab; 2017 Oct 26; 30(10):1095-1103. PubMed ID: 28862987
    [Abstract] [Full Text] [Related]

  • 5. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, Colclough K, Ellard S, Byrne MM.
    Diabet Med; 2016 Jul 26; 33(7):976-84. PubMed ID: 26479152
    [Abstract] [Full Text] [Related]

  • 6. Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.
    Campos Franco P, Santos de Santana L, Dantas Costa-Riquetto A, Santomauro Junior AC, Jorge AAL, Gurgel Teles M.
    Diabetes Res Clin Pract; 2022 May 26; 187():109875. PubMed ID: 35472491
    [Abstract] [Full Text] [Related]

  • 7. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH.
    Dan Med J; 2015 Sep 26; 62(9):. PubMed ID: 26324089
    [Abstract] [Full Text] [Related]

  • 8. Treatment of young patients with HNF1A mutations (HNF1A-MODY).
    Raile K, Schober E, Konrad K, Thon A, Grulich-Henn J, Meissner T, Wölfle J, Scheuing N, Holl RW, DPV Initiative the German BMBF Competence Network Diabetes Mellitus.
    Diabet Med; 2015 Apr 26; 32(4):526-30. PubMed ID: 25483937
    [Abstract] [Full Text] [Related]

  • 9. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
    Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, Ellard S, Farmer AJ, McCarthy MI, Owen KR.
    Diabetes Care; 2012 Jun 26; 35(6):1206-12. PubMed ID: 22432108
    [Abstract] [Full Text] [Related]

  • 10. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, Mrozinska S, Parpan T, Glodzik W, Ludwig-Galezowska A, Kiec-Wilk B, Klupa T, Malecki MT.
    Endocrine; 2017 Aug 26; 57(2):272-279. PubMed ID: 28593615
    [Abstract] [Full Text] [Related]

  • 11. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP, Bacon S, Pannu KK, Rizvi SR, Colclough K, Ellard S, Byrne MM.
    Diabetes Metab; 2011 Dec 26; 37(6):512-9. PubMed ID: 21683639
    [Abstract] [Full Text] [Related]

  • 12. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
    Urbanova J, Andel M, Potockova J, Klima J, Macek J, Ptacek P, Mat'oska V, Kumstyrova T, Heneberg P.
    Curr Pharm Des; 2015 Dec 26; 21(39):5736-48. PubMed ID: 26446475
    [Abstract] [Full Text] [Related]

  • 13. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
    Liu J, Xiao X, Zhang Q, Yu M.
    J Diabetes; 2023 Jun 26; 15(6):519-531. PubMed ID: 37226652
    [Abstract] [Full Text] [Related]

  • 14. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC, Cull CA, Frighi V, Holman RR.
    JAMA; 1999 Jun 02; 281(21):2005-12. PubMed ID: 10359389
    [Abstract] [Full Text] [Related]

  • 15. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.
    Diabetologia; 2015 Oct 02; 58(10):2247-53. PubMed ID: 26277380
    [Abstract] [Full Text] [Related]

  • 16. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
    Kyithar MP, Bonner C, Bacon S, Kilbride SM, Schmid J, Graf R, Prehn JH, Byrne MM.
    J Transl Med; 2013 Jun 26; 11():156. PubMed ID: 23803251
    [Abstract] [Full Text] [Related]

  • 17. Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes.
    Ming-Qiang Z, Yang-Li D, Ke H, Wei W, Jun-Fen F, Chao-Chun Z, Guan-Ping D.
    J Pediatr Endocrinol Metab; 2019 Jul 26; 32(7):759-765. PubMed ID: 31216263
    [Abstract] [Full Text] [Related]

  • 18. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
    Giuffrida FMA, Moises RS, Weinert LS, Calliari LE, Manna TD, Dotto RP, Franco LF, Caetano LA, Teles MG, Lima RA, Alves C, Dib SA, Silveiro SP, Dias-da-Silva MR, Reis AF, Brazilian Monogenic Diabetes Study Group (BRASMOD).
    Diabetes Res Clin Pract; 2017 Jan 26; 123():134-142. PubMed ID: 28012402
    [Abstract] [Full Text] [Related]

  • 19. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S, Colclough K.
    Hum Mutat; 2006 Sep 26; 27(9):854-69. PubMed ID: 16917892
    [Abstract] [Full Text] [Related]

  • 20. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
    Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT.
    Diabet Med; 2000 Jul 26; 17(7):543-5. PubMed ID: 10972586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.